AR and hepatocellular carcinoma: Considering the disappointing outcomes of anti-androgen and anti-AR therapies in HCC, which have provided limited clinical benefits for HCC patients, our focus primarily lies on exploring inhibitors targeting downstream target genes to address anti-AR mutations in HCC.